The company announces that Nasdaq Stockholm decided to halt trading in the company’s share as a result of share price movements.
Immunicum cannot assess whether these movements are related to information leakage from an ongoing negotiation for a development collaboration. The company therefore wishes to inform that Immunicum is in negotiations with a leading global pharmaceutical company regarding a development agreement for ilixadendel, an off the shelf cancer immune primer. It is currently not possible to assess whether these negotiations will lead to an agreement.
Potential collaboration agreement
Under the collaboration agreement being negotiated, Immunicum expects to get access to a checkpoint inhibitor to be combined with ilixadencel in the planned Phase II study, ILIAD. The agreement will not be associated with any payments to Immunicum.
Photo of Carlos de Sousa, CEO Immunicum